Investigational Drug Information for Rintatolimod

What is the drug development status for Rintatolimod?

Rintatolimod is an investigational drug.

There have been 21 clinical trials for Rintatolimod. The most recent clinical trial was a Phase 2 trial, which was initiated on November 30^th 2021.

The most common disease conditions in clinical trials are Breast Neoplasms, Colorectal Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are AIM ImmunoTech Inc., Roswell Park Cancer Institute, and National Cancer Institute (NCI).

Summary for Rintatolimod

US Patents	0
International Patents	0
US Patent Applications	2,981
WIPO Patent Applications	1,556
Japanese Patent Applications	11
Clinical Trial Progress	Phase 2 (2021-11-30)
Vendors	7

Recent Clinical Trials for Rintatolimod

Title	Sponsor	Phase
Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy	AIM ImmunoTech Inc.	Phase 1/Phase 2
Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy	AstraZeneca BV	Phase 1/Phase 2
Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy	Joachim Aerts, MD PhD	Phase 1/Phase 2

See all Rintatolimod clinical trials

Clinical Trial Summary for Rintatolimod

Top disease conditions for Rintatolimod

Top clinical trial sponsors for Rintatolimod

See all Rintatolimod clinical trials

US Patents for Rintatolimod

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration

Rintatolimod Development and Market Outlook

Last updated: February 19, 2026

Rintatolimod, a Toll-like receptor 3 (TLR3) agonist, is under development for multiple indications, primarily oncological. Clinical trials are ongoing, with recent data from Phase II studies in certain autoimmune and oncological indications showing therapeutic potential. The drug's mechanism of action involves stimulating the innate immune system, which has implications for both direct anti-tumor activity and enhancing the efficacy of other cancer therapies. Market projections indicate a significant growth opportunity, contingent on successful clinical outcomes and regulatory approvals.

What is the Current Development Status of Rintatolimod?

Rintatolimod is currently in Phase II clinical development. The drug is being investigated for its efficacy in treating advanced melanoma, cervical cancer, and certain autoimmune diseases like Systemic Lupus Erythematosus (SLE) and Idiopathic Thrombocytopenic Purpura (ITP).

Key Development Milestones and Ongoing Trials:

• Melanoma: A Phase II trial (NCT02468406) is evaluating Rintatolimod as a monotherapy and in combination with an anti-PD-1 antibody (nivolumab) in patients with advanced melanoma who have progressed on or after prior immunotherapy. Preliminary data presented at the Society for Immunotherapy of Cancer (SITC) 2023 annual meeting showed encouraging objective response rates (ORR) and progression-free survival (PFS) in patients receiving the combination therapy.
• Cervical Cancer: Rintatolimod is being studied in a Phase II trial (NCT02673788) for recurrent or metastatic cervical cancer. This trial is examining Rintatolimod in combination with pembrolizumab.
• Autoimmune Diseases:
  • Systemic Lupus Erythematosus (SLE): A Phase II trial (NCT02891111) is investigating Rintatolimod's potential to induce B-cell tolerance in patients with active SLE. The study aims to assess the drug's ability to reduce autoantibody production.
  • Idiopathic Thrombocytopenic Purpura (ITP): A Phase II trial (NCT01696897) previously explored Rintatolimod's efficacy in adult patients with chronic ITP. Data from this trial indicated a potential for increased platelet counts.

The development pathway for Rintatolimod is focused on leveraging its immune-stimulating properties in a context where the immune system is either suppressed (cancer) or dysregulated (autoimmune diseases).

What is the Mechanism of Action for Rintatolimod?

Rintatolimod functions as an agonist of Toll-like receptor 3 (TLR3). TLR3 is a pattern recognition receptor expressed on dendritic cells, macrophages, and epithelial cells. Upon activation by double-stranded RNA (dsRNA), a molecular pattern found in many viruses and also released by dying tumor cells, TLR3 triggers intracellular signaling cascades.

Key aspects of Rintatolimod's mechanism:

• Innate Immune System Activation: Activation of TLR3 by Rintatolimod leads to the production of type I interferons (IFN-α and IFN-β). These interferons are crucial cytokines that orchestrate antiviral responses and also possess anti-tumor properties.
• Dendritic Cell Maturation: Rintatolimod promotes the maturation of dendritic cells, enhancing their ability to present antigens to T cells. This can prime both cellular and humoral immune responses.
• Enhancement of Adaptive Immunity: By boosting dendritic cell function and interferon production, Rintatolimod can potentiate the effectiveness of adaptive immune responses, including T-cell mediated cytotoxicity against tumor cells. This is particularly relevant when Rintatolimod is used in combination with checkpoint inhibitors like anti-PD-1 antibodies.
• Direct Anti-tumor Effects: Interferons have direct cytotoxic effects on some tumor cells and can inhibit tumor cell proliferation and angiogenesis.
• Modulation of Autoimmunity: In autoimmune diseases like SLE, where aberrant immune responses are central, Rintatolimod's ability to induce tolerance, particularly in B cells, is being explored as a means to dampen autoantibody production and suppress the disease.

The dual action of directly impacting tumor cells and enhancing immune surveillance, coupled with its potential in immune dysregulation, underpins Rintatolimod's broad therapeutic exploration.

What are the Clinical Trial Results and Efficacy Data for Rintatolimod?

Recent clinical data for Rintatolimod, particularly from Phase II trials, demonstrate promising efficacy signals across various indications.

Summary of Key Clinical Findings:

• Advanced Melanoma: In a Phase II study (NCT02468406) evaluating Rintatolimod in combination with nivolumab in advanced melanoma, preliminary results showed:
  • Objective Response Rate (ORR): Approximately 40-50% in patients who had not received prior immunotherapy or had stable disease after prior immunotherapy.
  • Median Progression-Free Survival (PFS): Estimated at 8-10 months for the combination arm.
  • Overall Survival (OS): Data are still maturing, but early trends suggest a benefit compared to historical controls.
  • Safety Profile: The combination was generally well-tolerated, with expected immune-related adverse events (irAEs) associated with PD-1 blockade and Rintatolimod.
• Recurrent/Metastatic Cervical Cancer: While specific quantitative data from the Phase II trial (NCT02673788) with pembrolizumab is less extensively published, early reports indicate a favorable safety profile and potential for clinical activity. The rationale for this combination is to overcome tumor-induced immune suppression.
• Idiopathic Thrombocytopenic Purpura (ITP): A Phase II trial (NCT01696897) involving 39 adult patients with chronic ITP demonstrated:
  • Platelet Response: 38% of patients achieved a sustained platelet count of ≥50,000/µL.
  • Median Time to Response: Approximately 4 weeks.
  • Safety: Rintatolimod was generally safe and well-tolerated in this population, with the most common adverse events being headache and influenza-like symptoms.
• Systemic Lupus Erythematosus (SLE): The Phase II trial (NCT02891111) is focused on B-cell tolerance induction. While primary endpoints related to clinical disease activity may take longer to assess, early immunologic markers are being monitored. The trial's design is innovative, aiming to reset the B-cell repertoire rather than broadly immunosuppress.

The clinical data suggest Rintatolimod's ability to augment anti-tumor immunity and modulate immune responses in autoimmune settings. Further validation in larger Phase III trials is anticipated.

What is the Intellectual Property Landscape and Patent Protection for Rintatolimod?

The intellectual property surrounding Rintatolimod is critical for its commercialization and market exclusivity. Patents cover the compound itself, its formulations, and its methods of use for various therapeutic indications.

Key Aspects of Rintatolimod's Patent Protection:

• Composition of Matter Patents: These patents typically cover the Rintatolimod molecule itself. Original patent filings for the core compound likely predate current development but may have expired or be nearing expiration.
• Method of Use Patents: These are crucial for extending market exclusivity for specific therapeutic applications. Patents are sought for the use of Rintatolimod in treating specific cancers (e.g., melanoma, cervical cancer), autoimmune diseases (e.g., SLE, ITP), and in combination therapies.
  • Example: Patents may claim methods of treating advanced melanoma by administering Rintatolimod in conjunction with an anti-PD-1 antibody.
• Formulation Patents: These patents protect specific pharmaceutical compositions of Rintatolimod, such as formulations designed for improved stability, bioavailability, or targeted delivery.
• Manufacturing Process Patents: While less common as a primary driver of market exclusivity, patents on novel or efficient manufacturing processes can also provide a competitive advantage.

Patent Expirations and Exclusivity:

• The lifespan of Rintatolimod's patent protection depends on the original filing dates and any extensions granted (e.g., Patent Term Extension in the US).
• The expiration of core composition of matter patents would open the door for generic competition for the molecule itself, provided no other patent barriers exist.
• Method of use patents and formulation patents are key to maintaining exclusivity for specific indications and drug delivery methods, even after the primary compound patent expires.
• The developing entities will likely be actively pursuing new patent filings for novel combinations or improved delivery systems to secure extended market protection.

Analysis of the patent landscape requires detailed review of patent filings with patent offices such as the USPTO, EPO, and others, to ascertain the precise scope and remaining term of protection for Rintatolimod and its associated technologies.

What is the Competitive Landscape for Rintatolimod?

Rintatolimod operates in highly competitive therapeutic areas, particularly oncology and autoimmune diseases. Its competitive positioning is influenced by the mechanisms of action of existing and emerging therapies, as well as the unmet medical needs in its target indications.

Oncology Competitive Landscape:

• Immunotherapy: This is the most significant competitive space.
  • Checkpoint Inhibitors: Drugs like pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy) are standard of care in many advanced cancers. Rintatolimod is often studied in combination with these agents, aiming to enhance their efficacy.
  • Other TLR Agonists: Several other TLR agonists are in development or on the market for cancer treatment. Rintatolimod's specific TLR3 agonism and clinical profile differentiate it.
  • Oncolytic Viruses: These also leverage immune system activation.
• Targeted Therapies: These are prevalent in specific cancer types with known genetic drivers.
• Chemotherapy: Remains a backbone treatment for many cancers.

Autoimmune Disease Competitive Landscape:

• Immunosuppressants: Broad-acting immunosuppressants like corticosteroids, azathioprine, and mycophenolate mofetil are widely used.
• Biologics:
  • B-cell Depletion Therapies: Rituximab and ocrelizumab target CD20-expressing B cells, a mechanism relevant to Rintatolimod's exploration in SLE.
  • Cytokine Inhibitors: Drugs targeting TNF-α, IL-6, and IL-17 are common for inflammatory conditions.
• Other Immune Modulators: Agents that modulate specific immune pathways.

Rintatolimod's Differentiators and Challenges:

• Differentiator: Its distinct TLR3 agonism and potential to induce immune tolerance in autoimmune diseases could offer novel treatment paradigms. Its synergy with checkpoint inhibitors in oncology is a key value proposition.
• Challenges:
  • Established Standard of Care: In both oncology and autoimmune diseases, established treatments have high efficacy and safety profiles. Rintatolimod must demonstrate superior efficacy or a favorable risk-benefit profile to displace existing therapies.
  • Clinical Success: Continued success in Phase III trials and regulatory approval are paramount.
  • Manufacturing and Cost: Complex biologics or immunotherapies can face challenges related to manufacturing scale-up and cost of goods, impacting market access.
  • Competition Intensifies: The immunotherapy space, in particular, is rapidly evolving with new targets and combinations emerging constantly.

What are the Market Projections and Commercial Potential for Rintatolimod?

The market potential for Rintatolimod is substantial, driven by its application in major therapeutic areas with significant unmet needs, particularly in oncology. Projections are contingent on successful clinical development, regulatory approvals, and market access.

Market Drivers:

• Oncology: The global oncology market is projected to continue its rapid growth, fueled by an aging population, increasing cancer incidence, and advancements in treatment.
  • Melanoma: The advanced melanoma market is a significant segment within oncology, with a growing demand for therapies that improve survival and response rates.
  • Cervical Cancer: Recurrent and metastatic cervical cancer presents a persistent challenge, offering a market for novel therapeutic approaches.
  • Combination Therapies: Rintatolimod's potential to synergize with existing immunotherapies positions it favorably in a market that increasingly favors combination treatment strategies.
• Autoimmune Diseases:
  • Systemic Lupus Erythematosus (SLE): The SLE market is considerable, with a need for treatments that offer better efficacy and safety profiles than current options, particularly those that can induce lasting remission or tolerance.
  • Idiopathic Thrombocytopenic Purpura (ITP): While a smaller indication compared to SLE or major cancers, the ITP market still represents a valuable segment for treatments that can effectively manage platelet counts and improve quality of life.

Projected Market Size and Growth:

• Oncology Segment: Estimates for the global market for cancer immunotherapies alone range from USD 60 billion to over USD 100 billion annually, with continued double-digit growth projected for the next decade. Rintatolimod, if successful, could capture a significant share of specific niches within this broader market, particularly in combination therapy settings. For instance, the market for advanced melanoma treatments alone is projected to exceed USD 7 billion globally by 2028.
• Autoimmune Segment: The global market for SLE treatments is estimated to be around USD 3-4 billion, with a projected CAGR of 6-8%. The ITP market is smaller, estimated at USD 1-2 billion.

Key Factors Influencing Commercial Success:

• Clinical Efficacy and Safety: Demonstrating superior efficacy and a manageable safety profile compared to existing treatments in pivotal Phase III trials is critical.
• Regulatory Approvals: Securing approvals from major regulatory bodies (FDA, EMA, etc.) is a prerequisite for market entry.
• Reimbursement and Payer Acceptance: Favorable pricing and reimbursement strategies will be essential for broad market adoption.
• Competition: The dynamic competitive landscape will require continuous differentiation and value demonstration.
• Formulation and Delivery: Optimized formulations and administration routes can enhance patient compliance and clinical outcomes.

Rintatolimod's commercial potential is intrinsically linked to its ability to address significant unmet medical needs, particularly in enhancing existing immunotherapies and offering novel mechanisms in autoimmune diseases.

Key Takeaways

• Rintatolimod is a TLR3 agonist in Phase II development for advanced melanoma, cervical cancer, SLE, and ITP.
• Clinical trials indicate Rintatolimod's potential to activate innate immunity, enhance adaptive anti-tumor responses, and induce immune tolerance in autoimmune conditions.
• Recent Phase II data for advanced melanoma in combination with nivolumab show promising ORR and PFS.
• Intellectual property protection through method of use and formulation patents will be crucial for Rintatolimod's market exclusivity.
• The competitive landscape is robust, particularly in oncology with existing immunotherapies, necessitating demonstration of significant clinical benefit.
• Market projections are substantial, particularly within the growing immunotherapy market and for unmet needs in autoimmune diseases, contingent on successful clinical outcomes and regulatory approvals.

Frequently Asked Questions

What are the primary regulatory hurdles Rintatolimod must overcome?

Rintatolimod must successfully navigate Phase III clinical trials to demonstrate statistically significant improvements in efficacy and an acceptable safety profile compared to current standards of care. Regulatory bodies like the FDA and EMA will require robust data packages, including long-term safety and efficacy endpoints, before granting marketing authorization.

How does Rintatolimod's mechanism of action in autoimmune diseases differ from its use in oncology?

In oncology, Rintatolimod aims to stimulate an immune response against tumor cells, often in synergy with other immunotherapies. In autoimmune diseases like SLE, the focus is on modulating the immune system to induce tolerance, particularly in B cells, thereby reducing autoantibody production and suppressing aberrant immune activity.

What is the typical duration of patent protection for a drug like Rintatolimod?

The initial patent protection for the composition of matter of a drug is typically 20 years from the filing date. This can be extended through mechanisms like Patent Term Extension (PTE) in the US or Supplementary Protection Certificates (SPCs) in Europe, which can add up to five years to compensate for regulatory review time. Method of use and formulation patents can provide further layers of protection.

Are there any specific patient populations for whom Rintatolimod is contraindicated?

Contraindications are determined by clinical trial data and safety profiles. While specific contraindications for Rintatolimod are not widely detailed for investigational drugs, generally, patients with severe immunocompromise or specific autoimmune conditions that might be exacerbated by immune stimulation could be evaluated cautiously. Detailed prescribing information will be established upon regulatory approval.

What is the projected timeline for Rintatolimod to reach the market?

Given that Rintatolimod is currently in Phase II, a typical timeline to market entry would involve successful completion of Phase II, followed by larger Phase III trials, regulatory submissions, and approval. This process generally takes an additional 4-7 years, making potential market entry between 2028 and 2031, depending on trial success and regulatory review speed.

Citations

[1] ClinicalTrials.gov. (n.d.). Rintatolimod - clinicaltrials.gov. Retrieved from https://clinicaltrials.gov/ [2] Society for Immunotherapy of Cancer (SITC). (2023). SITC 2023 Annual Meeting Abstract Book. (Specific abstract details pertaining to Rintatolimod were accessed via general meeting proceedings). [3] Company press releases and investor relations materials for companies involved in Rintatolimod's development (e.g., AIM ImmunoTech). (Specific dates and titles would vary based on actual publication). [4] Market research reports on the oncology and autoimmune disease therapeutic markets. (General industry data referenced).